{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:20:35Z","timestamp":1778934035462,"version":"3.51.4"},"reference-count":166,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) remains a global health challenge that urgently calls for innovative therapeutic strategies. Chimeric antigen receptor T cell (CAR T) therapy has emerged as a promising avenue for HCC treatment. However, the therapeutic efficacy of CAR T immunotherapy in HCC patients is significantly compromised by some major issues including the immunosuppressive environment within the tumor, antigen heterogeneity, CAR T cell exhaustion, and the advanced risk for on-target\/off-tumor toxicity. To overcome these challenges, many ongoing preclinical and clinical trials are underway focusing on the identification of optimal target antigens and the decryption of the immunosuppressive milieu of HCC. Moreover, limited tumor infiltration constitutes a significant obstacle of CAR T cell therapy that should be addressed. The continuous effort to design molecular targets for CAR cells highlights the importance for a more practical approach for CAR-modified cell manufacturing. This review critically examines the current landscape of CAR T cell therapy for HCC, shedding light on the changes in innate and adaptive immune responses in the context of HCC, identifying potential CAR T cell targets, and exploring approaches to overcome inherent challenges. Ongoing advancements in scientific research and convergence of diverse treatment modalities offer the potential to greatly enhance HCC patients\u2019 care in the future.<\/jats:p>","DOI":"10.3390\/ijms25052631","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:47:30Z","timestamp":1708685250000},"page":"2631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4489-1485","authenticated-orcid":false,"given":"Ioanna","family":"Aggeletopoulou","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kalafateli","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, General Hospital of Patras, 26332 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-8209","authenticated-orcid":false,"given":"Christos","family":"Triantos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"djx030","DOI":"10.1093\/jnci\/djx030","article-title":"Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival","volume":"109","author":"Jemal","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chen, X., Liu, X., and Du, S. (2023). Unveiling the Role of Tumor-Infiltrating T Cells and Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review. Cancers, 15.","DOI":"10.3390\/cancers15205046"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"Morabito","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/annonc\/mdy510","article-title":"Correction to: \u201cHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u201d","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: Clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the Association between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5301\/tj.5000625","article-title":"Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity","volume":"103","author":"Inno","year":"2017","journal-title":"Tumori"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ahmad, U., Khan, Z., Ualiyeva, D., Amissah, O.B., Noor, Z., Khan, A., Zaman, N., Khan, M., Khan, A., and Ali, B. (2022). Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Adv. Cancer Biol.\u2014Metastasis, 4.","DOI":"10.1016\/j.adcanc.2022.100035"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ozer, M., and Goksu, S.Y. (2023). Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials. Cancers, 15.","DOI":"10.3390\/cancers15061808"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Loskog","year":"2006","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, C., Liu, J., Zhong, J.F., and Zhang, X. (2017). Engineering CAR-T cells. Biomark. Res., 5.","DOI":"10.1186\/s40364-017-0102-y"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective","volume":"2","author":"Smith","year":"2016","journal-title":"J. Cell. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: A quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Tiruneh","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Moreno, C., and Haynie, C. (2022). Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071493"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"780399","DOI":"10.3389\/fimmu.2021.780399","article-title":"Implementing Logic Gates for Safer Immunotherapy of Cancer","volume":"12","author":"Savanur","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2021-149263","article-title":"IF-Better Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy","volume":"138","author":"Haubner","year":"2021","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"ra132","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2009.179","article-title":"Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors","volume":"17","author":"Modlich","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"15040","DOI":"10.1038\/celldisc.2015.40","article-title":"Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA","volume":"1","author":"Bai","year":"2015","journal-title":"Cell Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature20165","article-title":"S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate","volume":"540","author":"Tyrakis","year":"2016","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Goc","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1084\/jem.183.4.1461","article-title":"Chronic inflammation caused by lymphotoxin is lymphoid neogenesis","volume":"183","author":"Kratz","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri1786","article-title":"Lymphoid neogenesis in chronic inflammatory diseases","volume":"6","author":"Aloisi","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3389\/fimmu.2018.01952","article-title":"Tertiary Lymphoid Structures: Autoimmunity Goes Local","volume":"9","author":"Pipi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1600-6143.2007.01756.x","article-title":"Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection","volume":"7","author":"Nasr","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Cai, D., Yu, H., Wang, X., Mao, Y., Liang, M., Lu, X., and Shen, X. (2023). Turning Tertiary Lymphoid Structures (TLS) into Hot Spots: Values of TLS in Gastrointestinal Tumors. Cancers, 15.","DOI":"10.3390\/cancers15020367"},{"key":"ref_63","first-page":"407","article-title":"Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention","volume":"7","author":"Lawand","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1267654","DOI":"10.3389\/fimmu.2023.1267654","article-title":"Mechanisms of tertiary lymphoid structure formation: Cooperation between inflammation and antigenicity","volume":"14","author":"Khanal","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Petitprez","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fimmu.2017.00767","article-title":"Tumor-Associated Tertiary Lymphoid Structures: Gene-Expression Profiling and Their Bioengineering","volume":"8","author":"Zhu","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"674375","DOI":"10.3389\/fimmu.2021.674375","article-title":"Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling","volume":"12","author":"Ganss","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4049\/jimmunol.2000873","article-title":"Tertiary Lymphoid Structures: Diversity in Their Development, Composition, and Role","volume":"206","year":"2021","journal-title":"J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"734593","DOI":"10.3389\/fonc.2021.734593","article-title":"IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8280","DOI":"10.1038\/ncomms9280","article-title":"NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures","volume":"6","author":"Carrega","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-immunol-041015-055649","article-title":"Chemokines and Chemokine Receptors in Lymphoid Tissue Dynamics","volume":"34","author":"Schulz","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e1322238","DOI":"10.1080\/2162402X.2017.1322238","article-title":"Tbet and IL-36\u03b3 cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment","volume":"6","author":"Weinstein","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2006.06.016","article-title":"Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure","volume":"25","author":"Lee","year":"2006","journal-title":"Immunity"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"675538","DOI":"10.3389\/fimmu.2021.675538","article-title":"Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy","volume":"12","author":"Aoyama","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.13868","article-title":"The evolution of T-cell depletion in haploidentical stem-cell transplantation","volume":"172","author":"Reisner","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/cei.12004","article-title":"T cell depletion in paediatric stem cell transplantation","volume":"172","author":"Booth","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/eji.201444539","article-title":"Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy","volume":"44","author":"Snook","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"618427","DOI":"10.3389\/fimmu.2020.618427","article-title":"Allogeneic CAR Cell Therapy-More Than a Pipe Dream","volume":"11","author":"Caldwell","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"627549","DOI":"10.3389\/fonc.2021.627549","article-title":"Strategies for Dodging the Obstacles in CAR T Cell Therapy","volume":"11","author":"Rahbarizadeh","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14712598.2018.1533951","article-title":"Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia","volume":"18","author":"Thomas","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/med.21455","article-title":"Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0006-291X(03)00908-2","article-title":"Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker","volume":"306","author":"Nakatsura","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_93","first-page":"14","article-title":"The role of glypican-3 in regulating Wnt in hepatocellular carcinomas","volume":"1","author":"Gao","year":"2011","journal-title":"Cancer Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13402-017-0364-2","article-title":"Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma","volume":"41","author":"Montalbano","year":"2018","journal-title":"Cell Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/ijc.29518","article-title":"High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy","volume":"137","author":"Haruyama","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e001875","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/hum.2016.025","article-title":"Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity","volume":"28","author":"Li","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1782728","DOI":"10.1155\/2021\/1782728","article-title":"Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma","volume":"2021","author":"Meng","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: A phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific GPC3\/PD-1 CAR-T cells for the treatment of HCC","volume":"62","author":"Li","year":"2023","journal-title":"Int. J. Oncol."},{"key":"ref_103","first-page":"690","article-title":"Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0167-4838(00)00104-7","article-title":"Structure and function of alpha-fetoprotein: A biophysical overview","volume":"1480","author":"Gillespie","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2019.11.043","article-title":"Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression","volume":"471","author":"Xue","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2174\/0929867327999200729151247","article-title":"Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance","volume":"28","author":"Li","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Schmohl, J.U., and Vallera, D.A. (2016). CD133, Selectively Targeting the Root of Cancer. Toxins, 8.","DOI":"10.3390\/toxins8060165"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2009.12.030","article-title":"Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma","volume":"52","author":"Kohga","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1742-1241.2008.01777.x","article-title":"Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma","volume":"62","author":"Song","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1846926","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: A single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yang, C., You, J., Pan, Q., Tang, Y., Cai, L., Huang, Y., Gu, J., Wang, Y., Yang, X., and Du, Y. (2023). Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC Med., 21.","DOI":"10.1186\/s12916-023-03016-0"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Wang, H., Wang, X., Ye, X., Ju, Y., Cao, N., Wang, S., and Cai, J. (2022). Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09861-1"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1149931","DOI":"10.3389\/fimmu.2023.1149931","article-title":"Role of CD147 in the development and diagnosis of hepatocellular carcinoma","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_116","first-page":"2276","article-title":"Regulation of MMP-1 and MMP-2 production through CD147\/extracellular matrix metalloproteinase inducer interactions","volume":"61","author":"Sun","year":"2001","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/hepr.12320","article-title":"Expression and clinical implications of HAb18G\/CD147 in hepatocellular carcinoma","volume":"45","author":"Zhu","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clinre.2018.09.006","article-title":"A meta-analysis of the efficacy and safety of iodine [(131)I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma","volume":"43","author":"Fan","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zhang, R.Y., Wei, D., Liu, Z.K., Yong, Y.L., Wei, W., Zhang, Z.Y., Lv, J.J., Zhang, Z., Chen, Z.N., and Bian, H. (2019). Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00233"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2015.00097","article-title":"NKG2D Ligands in Tumor Immunity: Two Sides of a Coin","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omtm.2021.02.023","article-title":"Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells","volume":"21","author":"Tay","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother. Adv."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijsu.2018.06.025","article-title":"The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis","volume":"56","author":"Zhou","year":"2018","journal-title":"Int. J. Surg."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2009.10.026","article-title":"EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma","volume":"52","author":"Terris","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-07-6013","article-title":"EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma","volume":"68","author":"Yamashita","year":"2008","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1089\/hum.2018.229","article-title":"Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer","volume":"30","author":"Zhang","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ejca.2008.01.022","article-title":"Molecular cancer therapy: Can our expectation be MET?","volume":"44","author":"Migliore","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-08-1306","article-title":"Novel therapeutic inhibitors of the c-Met signaling pathway in cancer","volume":"15","author":"Eder","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1073\/pnas.0306068101","article-title":"Hepatocyte growth factor\/c-met signaling pathway is required for efficient liver regeneration and repair","volume":"101","author":"Huh","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.3748\/wjg.v21.i18.5445","article-title":"MET inhibitors for treatment of advanced hepatocellular carcinoma: A review","volume":"21","author":"Qi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.21037\/atm-20-3387","article-title":"The role of c-MET inhibitors in advanced hepatocellular carcinoma: Now and future","volume":"8","author":"Woo","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"546586","DOI":"10.3389\/fonc.2021.546586","article-title":"Bispecific c-Met\/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7555\/JBR.35.20200207","article-title":"c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo","volume":"36","author":"Huang","year":"2021","journal-title":"J. Biomed. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","article-title":"Tyrosine kinase signaling-independent MET-targeting with CAR-T cells","volume":"21","author":"Qin","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: Function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"19264","DOI":"10.18632\/oncotarget.4267","article-title":"Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3724\/SP.J.1008.2014.01177","article-title":"Specific cytotoxicity of MUC1 chimeric antigen receptor-engineered Jurkat T cells against hepatocellular carcinoma","volume":"35","author":"Ma","year":"2014","journal-title":"Acad. J. Second. Mil. Med. Univ."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CJI.0000000000000460","article-title":"Development of Engineered CAR T Cells Targeting Tumor-Associated Glycoforms of MUC1 for the Treatment of Intrahepatic Cholangiocarcinoma","volume":"46","author":"Mao","year":"2023","journal-title":"J. Immunother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jb\/mvq034","article-title":"Dlk-1, a cell surface antigen on foetal hepatic stem\/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency","volume":"148","author":"Yanai","year":"2010","journal-title":"J. Biochem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/liv.15411","article-title":"DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma","volume":"42","author":"Zhai","year":"2022","journal-title":"Liver Int."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21873\/anticanres.11430","article-title":"Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition","volume":"37","author":"Yoshikawa","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: Phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Hu, W., Huang, X., Huang, X., Chen, W., Hao, L., and Chen, Z. (2019). Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection. Biomed. Pharmacother., 118.","DOI":"10.1016\/j.biopha.2019.109333"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1800033","article-title":"Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma","volume":"203","author":"Liu","year":"2019","journal-title":"J. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00262-018-2221-1","article-title":"Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein","volume":"67","author":"Pan","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_153","first-page":"337","article-title":"Reconsidering CAR-T cell therapy for solid tumors","volume":"12","author":"Feng","year":"2019","journal-title":"J. Med. Postgrad."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"44179","DOI":"10.18632\/oncotarget.6175","article-title":"Therapeutic potential of CAR-T cell-derived exosomes: A cell-free modality for targeted cancer therapy","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/thno.40291","article-title":"Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","article-title":"CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction","volume":"6","author":"Siriwon","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e1900192","DOI":"10.1002\/adma.201900192","article-title":"Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e75660","DOI":"10.7554\/eLife.75660","article-title":"De novo-designed transmembrane domains tune engineered receptor functions","volume":"11","author":"Elazar","year":"2022","journal-title":"eLife"},{"key":"ref_162","first-page":"886","article-title":"The research advances of CAR-T cell therapy in solid tumor","volume":"12","author":"Li","year":"2019","journal-title":"J. Med. Postgrad."},{"key":"ref_163","first-page":"1846","article-title":"The killing effect of novel bi-specific Trop2\/PD-L1 CAR-T cell targeted gastric cancer","volume":"9","author":"Zhao","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"Teng","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur. J. Haematol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:05Z","timestamp":1760105045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":166,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25052631"],"URL":"https:\/\/doi.org\/10.3390\/ijms25052631","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}